InsiderTrades.com logo
Dror Bashan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Dror Bashan Biography and Net Worth

President & Chief Executive Officer, Director of Protalix BioTherapeutics

Mr. Bashan has served as our President and Chief Executive Officer and a director since June 2019. He has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance which provides him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE:TEVA). Most recently, he served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management and an MBA from the Tel Aviv University.

What is Dror Bashan's net worth?

The estimated net worth of Dror Bashan is at least $454.32 thousand as of December 19th, 2025. Mr. Bashan owns 188,516 shares of Protalix BioTherapeutics stock worth more than $454,324 as of July 21st. This net worth approximation does not reflect any other investments that Mr. Bashan may own. Learn More about Dror Bashan's net worth.

How do I contact Dror Bashan?

The corporate mailing address for Mr. Bashan and other Protalix BioTherapeutics executives is 2 University Plaza, Suite 100, Hackensack, NJ 07601, United States. Protalix BioTherapeutics can also be reached via phone at 201-696-9345 and via email at [email protected]. Learn More on Dror Bashan's contact information.

Has Dror Bashan been buying or selling shares of Protalix BioTherapeutics?

Dror Bashan has not been actively trading shares of Protalix BioTherapeutics over the course of the past ninety days. Most recently, on Friday, December 19th, Dror Bashan bought 56,000 shares of Protalix BioTherapeutics stock. The stock was acquired at an average cost of $1.81 per share, with a total value of $101,360.00. Following the completion of the transaction, the chief executive officer now directly owns 188,516 shares of the company's stock, valued at $341,213.96. Learn More on Dror Bashan's trading history.

Who are Protalix BioTherapeutics' active insiders?

Protalix BioTherapeutics' insider roster includes Amos Bar-Shalev (Director), and Dror Bashan (President & Chief Executive Officer, Director). Learn More on Protalix BioTherapeutics' active insiders.

Are insiders buying or selling shares of Protalix BioTherapeutics?

In the last year, Protalix BioTherapeutics insiders bought shares 1 times. They purchased a total of 56,000 shares worth more than $101,360.00. In the last year, insiders at the sold shares 2 times. They sold a total of 336 shares worth more than $628.32. The most recent insider tranaction occured on December, 19th when CEO Dror Bashan bought 56,000 shares worth more than $101,360.00. Insiders at Protalix BioTherapeutics own 6.7% of the company. Learn More about insider trades at Protalix BioTherapeutics.

Information on this page was last updated on 12/19/2025.

Dror Bashan Insider Trading History at Protalix BioTherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2025Buy56,000$1.81$101,360.00188,516View SEC Filing Icon  
10/19/2023Buy64,516$1.40$90,322.40132,516View SEC Filing Icon  
4/11/2022Buy68,000$1.50$102,000.0068,000View SEC Filing Icon  
See Full Table

Dror Bashan Buying and Selling Activity at Protalix BioTherapeutics

This chart shows Dror Bashan's buying and selling at Protalix BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Protalix BioTherapeutics Company Overview

Protalix BioTherapeutics logo
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Read More

Today's Range

Now: $2.41
Low: $2.38
High: $2.45

50 Day Range

MA: $2.15
Low: $1.90
High: $2.44

2 Week Range

Now: $2.41
Low: $1.41
High: $3.19

Volume

643,807 shs

Average Volume

977,520 shs

Market Capitalization

$194.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A